Performance of the Twist Biosciences versus the Biofire Respiratory Panel

Elizabeth Kalimeris 1, Nicole Stoesser 1,2
1 Oxford University Hospitals NHS Foundation Trust(OUH NHS FT), Microbiology Department - Oxford (OX3 9DU), 2 Nuffield Department of Medicine, University of Oxford - Oxford (OX3 9DU).

Keywords: Respiratory viruses; diagnostics; sequencing; SARS-CoV-2; Rhinovirus

Introduction
Respiratory tract infections (RTI) are a common cause of infection in children with a range of manifestations that can vary from mild to severe symptoms. In the OUH NHS FT Microbiology Department, the BioFire FilmArray respiratory 2.1 (RP2.1) panel which requires nasopharyngeal swabs (NPA) is the current gold standard for RTI detection. The RP2.1 panel is a cartridge-based nested PCR assay detecting 19 respiratory viruses but does not provide genomic information. Twist Biosciences have developed a respiratory virus panel (RVR) detecting 29 human respiratory viruses using >40K probes to enrich viral sequences prior to sequencing.

Aims
Comparison of the results of NPA and saliva samples tested both on the Biofire RP2.1 and Twist RVR panels, utilising both simulated and real clinical samples from paediatric patients who were admitted to the OUH NHS FT between January 2021-July 2022 with respiratory symptoms.

Methods
Thirty paired NPA and saliva children’s samples were tested on the RP2.1 panel. Eleven of these paired patient samples were then tested on the RVR panel. To evaluate the RVR panel, three synthetic controls containing InfluenzaH3N2, Human Rhinovirus89 and SARS-CoV-2, Gene expression universal human RNA and negative NPA from patients' samples were also tested.

Results
The results from the RP2.1 panel showed a 76% concordance of results between NPA and saliva samples.

For simulated experiments, genome coverage >90% was achieved at inputs >10^3 virus copies/mL for all viruses, and thresholds for detection were met at inputs >10^6 virus copies/mL. Issues with specificity were observed, with cross-reactivity between similar viruses. For 21 clinical samples (n=11 patients), results generated using the RVR panel were strictly concordant with those generated by BioFire RP2.1 in 8/21 (38%) cases.

Discussion and Conclusion
The findings from this evaluation lend support to the use of saliva as an alternative sample on both the RP2.1 and the RVR panel. The use of the RVR panel on patient samples highlighted its major advantage over the RP2.1 panel in its capacity to distinguish between Rhinovirus and Enterovirus infections, as well as the detection of Human Bocavirus in a patient sample which is not currently detected by the RP2.1 panel.

References